[1]Patent:US2004/73024,2004,A1,.Locationinpatent:Page38
[2]Patent:US2004/73024,2004,A1,.Locationinpatent:Page39
[1]Patent:US2014/58081,2014,A1,.Locationinpatent:Paragraph0049;0050
[1]Patent:US2014/58081,2014,A1,.Locationinpatent:Paragraph0047
[1]Patent:US2014/58081,2014,A1,
Title: A single supratherapeutic dose of ridaforolimus does not prolong the QTc interval in patients with advanced cancer.
Journal: Cancer chemotherapy and pharmacology 20121001
Title: Dual targeting of the Akt/mTOR signaling pathway inhibits castration-resistant prostate cancer in a genetically engineered mouse model.
Journal: Cancer research 20120901
Title: Clinical trial end points for assessing efficacy of novel therapies for soft-tissue sarcomas.
Journal: Expert review of anticancer therapy 20120901
Title: A role for maintenance therapy in managing sarcoma.
Journal: Cancer treatment reviews 20120801
Title: Synergistic activity of the mTOR inhibitor ridaforolimus and the antiandrogen bicalutamide in prostate cancer models.
Journal: International journal of oncology 20120801
Title: [Soft-tissue sarcoma: recent developments].
Journal: Deutsche medizinische Wochenschrift (1946) 20120801
Title: The minimal impact of food on the pharmacokinetics of ridaforolimus.
Journal: Cancer chemotherapy and pharmacology 20120701
Title: Analysis of the pharmacodynamic activity of the mTOR inhibitor ridaforolimus (AP23573, MK-8669) in a phase 1 clinical trial.
Journal: Cancer chemotherapy and pharmacology 20120501
Title: The effect of multiple doses of rifampin and ketoconazole on the single-dose pharmacokinetics of ridaforolimus.
Journal: Cancer chemotherapy and pharmacology 20120501
Title: Ridaforolimus for patients with progressive or recurrent malignant glioma: a perisurgical, sequential, ascending-dose trial.
Journal: Cancer chemotherapy and pharmacology 20120401
Title: Phase I study for ridaforolimus, an oral mTOR inhibitor, in Japanese patients with advanced solid tumors.
Journal: Cancer chemotherapy and pharmacology 20120401
Title: Regulation of physiologic actions of LRRK2: focus on autophagy.
Journal: Neuro-degenerative diseases 20120401
Title: mTOR inhibitors and its role in the treatment of head and neck squamous cell carcinoma.
Journal: Current treatment options in oncology 20120301
Title: [PI3K-AKT-mTOR pathway and cancer].
Journal: Bulletin du cancer 20120201
Title: Phase II study of the mammalian target of rapamycin inhibitor ridaforolimus in patients with advanced bone and soft tissue sarcomas.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20120101
Title: Antitumor activity of ridaforolimus and potential cell-cycle determinants of sensitivity in sarcoma and endometrial cancer models.
Journal: Molecular cancer therapeutics 20111001
Title: Clinical presentation and management of mTOR inhibitor-associated stomatitis.
Journal: Oral oncology 20111001
Title: Ridaforolimus: a promising drug in the treatment of soft-tissue sarcoma and other malignancies.
Journal: Future oncology (London, England) 20110701
Title: Ridaforolimus (AP23573; MK-8669), a potent mTOR inhibitor, has broad antitumor activity and can be optimally administered using intermittent dosing regimens.
Journal: Molecular cancer therapeutics 20110601
Title: Phase I studies of drug combinations.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20101020
Title: Phase IB study of the mTOR inhibitor ridaforolimus with capecitabine.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20101020
Title: Ridaforolimus.
Journal: Drugs in R&D 20100901
Title: Phase Ib study of weekly mammalian target of rapamycin inhibitor ridaforolimus (AP23573; MK-8669) with weekly paclitaxel.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology 20100601
Title: Emergent toxicities associated with the use of mTOR inhibitors in patients with advanced renal carcinoma.
Journal: Anti-cancer drugs 20100601
Title: [Treatment of adult patients with metastatic sarcoma: current shift in concepts].
Journal: Bulletin du cancer 20100601
Title: Preliminary characterization of oral lesions associated with inhibitors of mammalian target of rapamycin in cancer patients.
Journal: Cancer 20100101
Title: Targeted therapy in lymphoma.
Journal: Journal of hematology & oncology 20100101
Title: Exploring mammalian target of rapamycin (mTOR) inhibition for treatment of mantle cell lymphoma and other hematologic malignancies.
Journal: Leukemia & lymphoma 20091201
Title: [Targeted therapies and their indications in solid neoplasias].
Journal: La Revue de medecine interne 20090501
Title: The applicability of mTOR inhibition in solid tumors.
Journal: Current cancer drug targets 20090501
Title: The pharmacology of mTOR inhibition.
Journal: Science signaling 20090421
Title: Targeting the mTOR pathway using deforolimus in cancer therapy.
Journal: Future oncology (London, England) 20090401
Title: A phase I trial to determine the safety, tolerability, and maximum tolerated dose of deforolimus in patients with advanced malignancies.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20090215
Title: [Topics in mTOR pathway and its inhibitors].
Journal: Bulletin du cancer 20090101
Title: NCCN Task Force Report: mTOR inhibition in solid tumors.
Journal: Journal of the National Comprehensive Cancer Network : JNCCN 20080901
Title: A phase 2 clinical trial of deforolimus (AP23573, MK-8669), a novel mammalian target of rapamycin inhibitor, in patients with relapsed or refractory hematologic malignancies.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20080501
Title: Molecular target therapies in endometrial cancer: from the basic research to the clinic.
Journal: Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology 20080501
Title: Drug essentials mTOR inhibitors.
Journal: Oncology (Williston Park, N.Y.) 20080401
Title: Phospho-S6 ribosomal protein: a potential new predictive sarcoma marker for targeted mTOR therapy.
Journal: Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 20080301
Title: The potential role of mTOR inhibitors in non-small cell lung cancer.
Journal: The oncologist 20080201
Title: mTOR: the mammalian target of replication.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20080120
Title: Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20080120
Title: Mammalian target of rapamycin as a target in hematological malignancies.
Journal: Current problems in cancer 20080101
Title: [mTOR signal pathway and its inhibitors in antitumor therapy: a review].
Journal: Ai zheng = Aizheng = Chinese journal of cancer 20071201
Title: The biology behind mTOR inhibition in sarcoma.
Journal: The oncologist 20070801
Title: Mechanisms of mammalian target of rapamycin inhibition in sarcoma: present and future.
Journal: Expert review of anticancer therapy 20070801
Title: The role of mTOR inhibitors for treatment of sarcomas.
Journal: Current oncology reports 20070701
Title: Clinical development of mTOR inhibitors: a focus on lymphoma.
Journal: Reviews on recent clinical trials 20070501
Title: New therapeutics for soft-tissue sarcomas in adults.
Journal: Oncology (Williston Park, N.Y.) 20070101
Title: Drug evaluation: AP-23573--an mTOR inhibitor for the treatment of cancer.
Journal: IDrugs : the investigational drugs journal 20060901
Title: Recent developments in targeting the mammalian target of rapamycin (mTOR) kinase pathway.
Journal: Anti-cancer drugs 20060601
Title: Rivera VM, et al. Deforolimus (AP23573; MK-8669), a potent mTOR inhibitor, has broad antitumor activity and can be optimally administered using intermittent dosing regimens. Mol Cancer Ther. 2011 Jun;10(6):1059-71.
Title: Brandt M, et al. mTORC1 Inactivation Promotes Colitis-Induced Colorectal Cancer but Protects from APC Loss-Dependent Tumorigenesis. Cell Metab. 2018 Jan 9;27(1):118-135.e8.
